NASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis $12.68 -0.50 (-3.76%) As of 09:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Denali Therapeutics Stock (NASDAQ:DNLI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Denali Therapeutics alerts:Sign Up Key Stats Today's Range$13.00▼$13.2050-Day Range$11.47▼$22.2552-Week Range$10.57▼$33.33Volume11,065 shsAverage Volume1.08 million shsMarket Capitalization$1.84 billionP/E RatioN/ADividend YieldN/APrice Target$37.57Consensus RatingBuy Company OverviewDenali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Read More… Remove Ads Denali Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreDNLI MarketRank™: Denali Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 132nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDenali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDenali Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Denali Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.71) to ($3.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Denali Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.10% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Denali Therapeutics has recently increased by 8.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.84 Percentage of Shares Shorted9.10% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Denali Therapeutics has recently increased by 8.85%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.68 News SentimentDenali Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Denali Therapeutics this week, compared to 6 articles on an average week.Search Interest4 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows8 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.90% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Stock News HeadlinesCantor Fitzgerald Analysts Cut Earnings Estimates for DNLIApril 14 at 1:33 AM | americanbankingnews.comDenali Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldApril 10, 2025 | markets.businessinsider.comTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you ready for it?April 16, 2025 | Porter & Company (Ad)Denali Initiates BLA Filing For Accelerated Approval Of Hunter Syndrome TreatmentApril 4, 2025 | nasdaq.comWilliam Blair Sticks to Their Buy Rating for Denali Therapeutics (DNLI)April 3, 2025 | markets.businessinsider.comDenali initiates BLA filing for accelerated approval of tividenofusp alfaApril 2, 2025 | markets.businessinsider.comDenali Therapeutics set to advance groundbreaking treatments for neurological diseasesApril 2, 2025 | msn.comDenali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START ProgramApril 2, 2025 | globenewswire.comSee More Headlines DNLI Stock Analysis - Frequently Asked Questions How have DNLI shares performed this year? Denali Therapeutics' stock was trading at $20.38 on January 1st, 2025. Since then, DNLI shares have decreased by 37.8% and is now trading at $12.6750. View the best growth stocks for 2025 here. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings data on Thursday, February, 27th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08. When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Top institutional investors of Denali Therapeutics include SG Americas Securities LLC (0.03%), Breakwater Capital Group (0.01%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Marc Tessier-Lavigne, Ryan J Watts, Carole Ho, Alexander O Schuth, Vicki L Sato, Steve E Krognes and Jennifer E Cook. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings2/27/2025Today4/16/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DNLI CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees430Year Founded2015Price Target and Rating Average Stock Price Target$37.57 High Stock Price Target$87.00 Low Stock Price Target$24.00 Potential Upside/Downside+185.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-145,220,000.00 Net MarginsN/A Pretax Margin-33,119.50% Return on Equity-32.94% Return on Assets-30.04% Debt Debt-to-Equity RatioN/A Current Ratio9.98 Quick Ratio9.98 Sales & Book Value Annual Sales$330.53 million Price / Sales5.79 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book1.77Miscellaneous Outstanding Shares145,215,000Free Float132,552,000Market Cap$1.91 billion OptionableOptionable Beta1.58 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:DNLI) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.